EZH2 and ALDH1 expression in ductal carcinoma in situ: Complex association with recurrence and progression to invasive breast cancer

Cell Cycle

Volumn 12, Issue 13, 2013, Pages 2042-2050

  Knudsen, Erik S ^a   Dervishaj, Ornella ^b   Kleer, Celina G ^c   Pajak, Thomas ^d   Schwartz, Gordon F ^b   Witkiewicz, Agnieszka K ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d NONE

Author keywords

ALDH1; DCIS; Ductal carcinoma in situ; EZH2; IBC; Invasive breast cancer; Prognostic markers; Tumor initiating cells

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; OXIDOREDUCTASE; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; DISEASE ASSOCIATION; FEMALE; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PATHOGENESIS; PROTEIN EXPRESSION; TUMOR INVASION; TUMOR MICROENVIRONMENT;

EID: 84879765041     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.25065     Document Type: Article

References (33)

1. Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, et al. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol 2009; 27:279-88; PMID:19064970; http://dx.doi.org/10.1200/ JCO.2008.18.3103
2. Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst 2010; 102:170-8; PMID:20071685; http://dx.doi.org/10.1093/jnci/ djp482
3. Allegra CJ, Aberle DR, Ganschow P, Hahn SM, Lee CN, Millon-Underwood S, et al. National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009. J Natl Cancer Inst 2010; 102:161-9; PMID:20071686; http://dx.doi.org/10.1093/jnci/ djp485
4. Wicha MS. Breast cancer stem cells: the other side of the story. Stem Cell Rev 2007; 3:110-2, discussion 113; PMID:17873342; http://dx.doi.org/10. 1007/s12015-007-0016-4
5. Liu S, Wicha MS. Targeting breast cancer stem cells. J Clin Oncol 2010; 28:4006-12; PMID:20498387; http://dx.doi.org/10.1200/JCO.2009.27.5388
6. Chang CJ, Hung MC. The role of EZH2 in tumour progression. Br J Cancer 2012; 106:243-7; PMID:22187039; http://dx.doi.org/10.1038/bjc.2011.551
7. Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH, et al. EZH2 promotes expansion of breast tumor-initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell 2011; 19:86-100; PMID:21215703; http://dx.doi.org/10.1016/j.ccr.2010.10.035
8. Dave B, Chang J. Treatment resistance in stem cells and breast cancer. J Mammary Gland Biol Neoplasia 2009; 14:79-82; PMID:19259795; http://dx.doi.org/ 10.1007/s10911-009-9117-9
9. Nakshatri H, Srour EF, Badve S. Breast cancer stem cells and intrinsic subtypes: controversies rage on. Curr Stem Cell Res Ther 2009; 4:50-60; PMID:19149630; http://dx.doi.org/10.2174/157488809787169110
10. Resetkova E, Reis-Filho JS, Jain RK, Mehta R, Thorat MA, Nakshatri H, et al. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat 2010; 123:97-108; PMID:19911270; http://dx.doi.org/10.1007/s10549-009-0619-3
11. Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin Cancer Res 2011; 17:2613-8; PMID:21367748; http://dx.doi.org/10.1158/1078-0432.CCR-10-2156
12. Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008; 647:21-9; PMID:18723033; http://dx.doi.org/10. 1016/j.mrfmmm.2008.07.010
13. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003; 22:5323-35; PMID:14532106; http://dx.doi.org/10.1093/emboj/ cdg542
14. Asangani IA, Harms PW, Dodson L, Pandhi M, Kunju LP, Maher CA, et al. Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget 2012; 3:1011-25; PMID:22948084
15. Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, De Marzo AM. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget 2011; 2:669-83; PMID:21941025
16. Marchesi I, Fiorentino FP, Rizzolio F, Giordano A, Bagella L. The ablation of EZH2 uncovers its crucial role in rhabdomyosarcoma formation. Cell Cycle 2012; 11:3828-36; PMID:22983009; http://dx.doi.org/10.4161/cc.22025
17. Tatton-Brown K, Hanks S, Ruark E, Zachariou A, Duarte SdelV, Ramsay E, et al.; Childhood Overgrowth Collaboration. Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height. Oncotarget 2011; 2:1127-33; PMID:22190405
18. Collett K, Eide GE, Arnes J, Stefansson IM, Eide J, Braaten A, et al. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 2006; 12:1168-74; PMID:16489070; http://dx.doi.org/10.1158/1078- 0432.CCR-05-1533
19. Ding L, Kleer CG. Enhancer of Zeste 2 as a marker of preneoplastic progression in the breast. Cancer Res 2006; 66:9352-5; PMID:17018586; http://dx.doi.org/10.1158/0008-5472.CAN-06-2384
20. Kunju LP, Cookingham C, Toy KA, Chen W, Sabel MS, Kleer CG. EZH2 and ALDH-1 mark breast epithelium at risk for breast cancer development. Mod Pathol 2011; 24:786-93; PMID:21399615; http://dx.doi.org/10.1038/modpathol.2011.8
21. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009; 69:1302-13; PMID:19190339; http://dx.doi.org/10.1158/0008-5472.CAN-08-2741
22. Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res 2010; 16:45-55; PMID:20028757; http://dx.doi.org/10.1158/1078-0432.CCR-09-1630
23. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1:555-67; PMID:18371393; http://dx.doi.org/10.1016/j.stem.2007.08.014
24. Ginestier C, Wicinski J, Cervera N, Monville F, Finetti P, Bertucci F, et al. Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle 2009; 8:3297-302; PMID:19806016; http://dx.doi.org/10.4161/cc.8.20.9761
25. Zeng XCS, Chen S, Huang H. Phosphorylation of EZH2 by CDK1 and CDK2: a possible regulatory mechanism of transmission of the H3K27me3 epigenetic mark through cell divisions. Cell Cycle 2011; 10:579-83; PMID:21278485; http://dx.doi.org/10.4161/cc.10.4.14722
26. Park SY, Lee HE, Li H, Shipitsin M, Gelman R, Polyak K. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 2010; 16:876-87; PMID:20103682; http://dx.doi.org/10.1158/1078-0432.CCR-09-1532
27. Schnitt SJ. Local outcomes in ductal carcinoma in situ based on patient and tumor characteristics. J Natl Cancer Inst Monogr 2010; 2010:158-61; PMID:20956823; http://dx.doi.org/10.1093/jncimonographs/lgq031
28. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003; 100:11606-11; PMID:14500907; http://dx.doi.org/10.1073/pnas.1933744100
29. Raaphorst FM, Meijer CJ, Fieret E, Blokzijl T, Mommers E, Buerger H, et al. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 2003; 5:481-8; PMID:14965441
30. Gauthier ML, Berman HK, Miller C, Kozakeiwicz K, Chew K, Moore D, et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell 2007; 12:479-91; PMID:17996651; http://dx.doi.org/10.1016/j.ccr.2007.10.017
31. Witkiewicz AK, Rivadeneira DB, Ertel A, Kline J, Hyslop T, Schwartz GF, et al. Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment. Am J Pathol 2011; 179:1171-8; PMID:21756866; http://dx.doi.org/10.1016/j.ajpath.2011.05.043
32. Rakovitch E, Nofech-Mozes S, Hanna W, Narod S, Thiruchelvam D, Saskin R, et al. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br J Cancer 2012; 106:1160-5; PMID:22361634; http://dx.doi.org/10.1038/bjc.2012.41
33. Kurebayashi J, Kanomata N, Shimo T, Yamashita T, Aogi K, Nishimura R, et al. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone. Breast Cancer 2012; PMID:22689016; http://dx.doi.org/ 10.1007/s12282-012-0380-z